finerenone.
a nonsteroidal antimineralocorticoid that is in phase III clinical trials for the treatment of chronic heart failure as of October 2015
FDA Approves Kerendia, First Type 1 CKD Drug
FDA approved Bayer's Kerendia on Sep 17, 2026 for type 1 diabetes CKD—the first new treatment in over 30 years—after FINE-ONE showed a 25% UACR cut versus placebo.
Health · 7 sources · Sep 17, 2026Read itThe journal
Open the journal →The conversation starts in the journal — be the first to post.
About finerenone
Finerenone, marketed under the brand name Kerendia among others, is a medication used to reduce the risk of kidney function decline, kidney failure, cardiovascular death, non-fatal myocardial infarctions, and hospitalization for heart failure in adults with chronic kidney disease associated with type 2 diabetes. In the United States, it is also approved to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visits in adults with heart failure and a left ventricular ejection fraction (LVEF) of 40% or greater. Finerenone is a non-steroidal mineralocorticoid receptor antagonist. It is taken orally.
Everything about finerenone →